This kit uses RT-PCR to detect rearranged during trasfection (RET) M918T, C634Y, and C634R mutations in plasma or formalin-fixed paraffin-embedded tissue (FFPE). Test results may serve as a reference for clinical evaluation of defined human RET gene mutations in targeted drug use and drug resistance for non-small cell lung cancer (NSCLC). Confirmed mutation: recommended medications include pratinib, selpercatinib, etc.
Based on high-efficiency enzymatic processing technology, the test uses specific gene sequences as PCR targets. Human geonomic sequence is used as internal quality control.
